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ABSTRACT 
 
 
JOSHUA MATTHEW NOONE. Demographics, side effects, and health care beliefs of 
prohormone users. (Under the direction of DR. YVETE HUET) 
 
 
Prohormones are a type of nutritional supplement similar to Anabolic-Androgenic 
Steroids (AAS).  As AAS are illegal without a medical prescription prohormones are 
sometimes used as a legal alternative.  It is thoughts that prohormones carry the same 
types of health risks associated with AAS, but there is little research to support this.  The 
study has focused on identifying a group of prohormone users and asking them about 
who they are, including demographics, how they use prohormones, what health outcomes 
they experience, and their perceptions of the health care system.  Data acquisition was 
accomplished via a survey posted to two online forums dedicated to prohormone use and 
the Facebook
TM
 page of a private gym facility.  The survey was created and administered 
in the SurveyShare
TM
 platform.  Sixty five usable responses were gathered from three 
months of survey run time, four of which had to be dropped from papers two and three 
for lack of pertinent information.  Demographics were identified including age, gender, 
and education along with use characteristic such as cycles taken per year.  These 
characteristics were tested to see if there existed differences in those who started use at an 
earlier age or a later age.  Self-reported health outcomes experienced were also identified 
and explored to assess any differences in outcomes based upon taking more than the 
recommended dose.  Finally health care beliefs were outlined such as belief in the 
information obtained from a physician and tested based upon being a prohormone users 
or a user of both prohormones and AAS
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CHAPTER 1: INTRODUCTION 
 
 
Background 
The increase of anabolic hormones in the human body has been the focus of 
research and controversy for more than fifty years.  Illicit use of these hormones is 
thought to cause severe negative health effects as well as controversies surrounding their 
use being cheating in sports and currently we classify these drugs as schedule three 
controlled substances.  Several different methods exist to increase anabolic hormone 
levels depending on the setting.  In a medical setting these hormones can be injected or 
increased via a transdermal patch (1-5).  The most common medically used anabolic 
hormones are synthetic versions of testosterone and the former prohormone turned 
prescription drug androstenedione.  In a non-medical setting anabolic hormones range 
across dozens of different hormones with similar structures but different development 
backgrounds.  Those substances that come from medical or veterinary backgrounds are 
frequently known as anabolic-androgenic steroids (AAS) and those with this designation 
are controlled substances that are illegal to possess without a prescription (1).  Hormones 
developed to increase physical performance and not intended for medical or veterinary 
use are made without the knowledge of the Food and Drug Administration and are legal.  
These hormones are commonly referred to as “prohormones” or less commonly as 
“designer steroids” (6).  However, these substances are not identical even though the 
terms are used interchangeably.  These differences will be discussed further under their 
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named sections, but for the general purposes of this paper the term prohormone will 
describe both substance types unless otherwise stated.  The major overarching differences 
between AAS and prohormones are their methods of administration and obtainability.  As 
mentioned previously AAS are most commonly administered intravenously or through a 
transdermal patch.  Prohormones are never administered intravenously as this would 
automatically change them from being nutritional supplements to prescription drugs (6).  
These substances are usually administered by pill, but also by transdermal cream or 
sublingual liquid.  From an obtainability standpoint AAS are prescription drugs and are 
usually obtained illegally from another country whereas prohormones are legal and easily 
purchased online.   
The Loop Hole 
 Prohormones exist because of an opening in the law created by the Controlled 
Substance Act of 1971 and the Dietary Supplement Act of 1994 (7, 8).  The largest 
loopholes exist because of the Controlled Substance Act, which is primarily concerned 
with any substance that has the potential for dependence.  These substances are then 
ranked from schedule one to schedule five based upon their medical need versus their 
potential for abuse.  Those with the most potential for abuse and little to no medical need 
are placed in schedule one with the opposite in schedule five.  AAS were added to the 
schedule in 1991 via the Omnibus Crime Act (9).  This was a highly controversial 
addition as the dependence capability of AAS was openly refuted by medical 
professionals called to testify in committee meetings on the topic (10).  AAS were added 
to schedule three of the controlled list with some stipulations that create the present day 
loopholes.  Most importantly AAS of any kind are not illegal as they have valid medical 
and veterinary uses.  This makes any drug enforcement involved with these substances 
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much more difficult as an individual may have a valid reason to possess them.  Secondly, 
any chemical difference no matter how small from a known AAS creates a new substance 
that must be congressionally reviewed before being added to the list.  In effect this means 
that any manipulation creates a new substance which is by default legal until determined 
otherwise.  This is where the Dietary Supplement Act becomes important.  These new 
substances are then marketed as dietary supplements and via the Dietary Supplement Act 
are outside the purview of the Food and Drug Administration (FDA).  The FDA simply 
needs to be notified that a new substance exists, they add it to the list of registered 
nutritional supplements, and it can be sold to the public, though enforcement on how 
often supplements are checked against FDA registrations is unknown (6).  A third piece 
of legislation was created after this topic received attention in the early 2000’s called the 
Anabolic Steroid Act of 2004.  With this new legislation a substance deemed to be an 
AAS by the head of the Drug Enforcement Agency can be designated as a controlled 
substance without going through congressional oversight.  This has been used on a few 
occasions since, most notably with the addition of the designer steroid Madol (11).  After 
all of these pieces of legislation what has effectively happened is the creation of an open 
market for small labs to create new substances, market them, and sell them as nutritional 
supplements without fear of repercussion. 
Prohormones 
 A prohormone is any hormonal substance that after administration converts into 
another hormonal substance.  This conversion is usually accomplished via the liver where 
a methyl group is cleaved off the molecular structure of the substance.  More specific to 
this context a prohormone is a substance that breaks down into an anabolic steroid (12).  
The most famous prohormone in United States history is androstenedione (Andro), which 
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is a naturally occurring hormone and is the last in a cascade of hormones that result in 
testosterone production (13).  In the late 1990’s nutritional supplement companies began 
marketing Andro as a way to increase testosterone levels without actually supplementing 
testosterone itself.  Retrospectively we now know that while Andro will convert to 
testosterone, it also commonly converts to estrogen in young men.  After being made 
famous in the early 2000’s by baseball player Mark McGwire, Andro became 
controversial and was eventually added to the list of known AAS making it a controlled 
substance illegal without a prescription (14).  At the same time some other famous 
prohormones were added to the list as well including Methyl 1-Testosterone and 19 Nor-
Andro (7). 
 Since Andro became a controlled substance other prohormones have become 
popular as nutritional supplements.  These substances also occur naturally in the body 
and are part of the hormonal cascade mentioned earlier, they are simply higher up the list.  
Androstenediol, one of the new substance, is the conversion before Androstenedione has 
been sold as well as Androstone and the “19 Nor” versions of each (2, 15).  To be 
effective each of these prohormones must first break down into Andro.  These substances 
are not perceived as being as effective as the original Andro and are therefore less 
popular accounting for less and less of the market share over time.  This gap in the 
market is being filled by designer steroids. 
Designer Steroids 
 Designer steroids are new anabolic substances sold as nutritional supplements.  
These substances are usually very similar to an existing AAS, mainly having one 
chemical difference between the new substance and the “parent hormone” (See Exhibit 
1).  In other cases they are entirely new substances such as THG made famous in the Bay 
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Area Lab Corporation (BALCO) trials involving performance enhancing drug use (PED) 
in several elite athletes including Barry Bonds (16).  These new substances are usually 
created to be highly anabolic while at the same time being entirely undetectable in drug 
tests (17).  Noted by Diel et al. and Frese et al. these new or slightly different substances, 
while chemically similar to other AAS, may have very different outcomes within the 
human body (2, 15).  As such there is no way to predict how any new substance will act 
or what health outcomes could be possible.  It is also the case that guidelines such as 
appropriate dosages are most often made up or taken from the experiences of a small 
experimental group including the chemists themselves and their associates.  With no legal 
oversight these substances can exist for years undetected as with the BALCO case.   
Paper 1 Demographics 
 Background demographics for prohormone users do not exist.  In light of this lack 
of information we must substitute demographics for AAS users.  Demographics for AAS 
users show a distinct split depending on the age of the subject in question.  Because of 
existing data and the ease of collecting new data while they are gathered together in 
school, children and adolescents are the most studied age groups (18, 19).  From this 
research it is evident that adolescent AAS users commonly participate in sports, are more 
likely to have body image concerns, use other illicit drugs, and miss school more than 
their non-using peers.  Moreover, reports on racial and socioeconomic status influences 
on AAS use have not been consistent and therefore cannot be used as a predictive factor 
at present. (19-23). 
 The demographics of adult AAS users contrast those of adolescent’s.  Of the few 
large studies investigating adult AAS users they tend to be well educated, employed, but 
not participants of sports activities (24, 25).  Some studies have shown that adult AAS 
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users suffer continued body image concerns and most studies agree that illicit drug use 
other than AAS is much higher than non-using peers, but whether this is a continued 
illicit drug use or is just a leftover artifact in the data from when they were adolescent is 
unclear (26).  With this seeming demographic divide depending on the age of the 
participants being studied this paper will assess any demographic differences between 
those who initiated prohormone use before the age of 30 versus those began use after the 
age of 30 years. 
Paper 2 Side Effects 
 Adverse health outcomes have been the focus of most PED research since 
nonprescription use began.  A limited amount of research has been conducted specifically 
to investigate prohormones.  In two case studies the prohormone Methasteron (Superdrol) 
was linked to advanced liver damage.  One of the two studies detailed a college student’s 
hospitalization after a little more than a month on the substance (27, 28). 
 AAS adverse health outcomes have been theorized and debated for decades, but 
some AAS adverse health outcomes are well accepted.  These include, but are not limited 
to, acne, hair loss, increased blood pressure, hyperlipidemia, increased feelings of anger, 
liver damage (oral AAS), elevated prostate specific antigen (PSA) levels (in 
dehydrotestosterone related AAS) and erectile dysfunction are all known as potential 
short term side effects meaning that they would likely return to normal within 
approximately six months of cessation (1, 3, 4, 13, 29-33).  The percentage of individuals 
who experience these outcomes is unclear and with more than one hundred different AAS 
products available, the combination of adverse health outcomes may be specific to the 
AAS used.   
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Longer term outcomes are more challenging to measure and evidence for specific 
long-term health outcomes in association with AAS use is lacking, except for 
gynecomastia, which is known to occur with testosterone AAS (29).  Other potential long 
term effects with AAS use include: heart disease, cancer, stroke and permanent prostate 
damage (32, 34-37).  While little research is associated with the effects of different 
dosage, pharmacological principles suggest that adverse events would increase with 
increased dosages.  Lack of research on this topic may have to do with the extreme doses 
that most AAS users use, when an individual uses 100 times the medical dose degrees of 
change in outcomes associated with each dosage potentially get lost (24). This study will 
look at the association of prohormone use with all of the short term and as many of the 
long-term effects health outcomes as possible.  Prohormone related health outcomes will 
then be compared between those taking the manufacturer recommended dose and those 
taking higher doses. 
Paper 3 Health Care Beliefs 
Patient beliefs about information coming from physicians have been studied for 
many years as it is an integral part of health care delivery.  Of the many studies in 
existence and measurement scales there appear to be differences in how a patient 
interacts with a health care provider based upon gender, race, age, and the physician’s 
physical appearance.  Pope et al found little difference in beliefs about health care 
provider credibility between AAS users and their non-using, weightlifting peers (38).  
The authors inquired about general health, illicit drug use, smoking, and many others 
with no differences found except for beliefs about nutritional supplements and AAS.  The 
AAS users believed less of a physician’s advice about AAS than their non-using peers 
and placed more credibility on information from “underground publications” dealing with 
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AAS use.  This disbelief is not unexpected as Yeselis and others have observed that 
adolescent do not believe the information they receive about AAS in school (23, 39) (40).  
Pope et al also reported that a large number of AAS users never discuss their use with 
their physicians, making it difficult to correctly diagnose and treat a set of symptoms(38).  
If a similar scenario exists in prohormone users, the implications for the medical 
community may include incorrect diagnosis of symptoms and harmful treatment. 
Significance 
 The obvious question to this topic is why anyone should care.  The answer is the 
potential outcomes associated with prohormone use.  There are no current estimates of 
prohormone use prevalence in the United States, but with online forums dedicated to 
discussing prohormones exceeding 50,000 members, prohormone use may include a 
significant sector of the population, emphasizing the urgency for further investigation.  
 Currently, the demographics of prohormone users and the type or dosage of 
prohormone use are not known.  Therefore, initial characterization of prohormone use 
and users is essential for future study as without this we will not know how to reach the 
individuals or, if deemed necessary, what methods of outreach would be prudent.  
Clinical health outcomes are difficult to measure because giving high doses of AAS or 
any dose of a prohormone to human beings in a lab setting would be unethical.  
Therefore, the present study will query individuals who are already taking prohormones, 
about their: 
 Health outcomes 
 Comfort in speaking to a physician about prohormones 
 Belief in the information a physician is giving about prohormones 
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If these users are seeking help for health outcomes, but do not feel comfortable speaking 
with a physician about prohormone use the physician may be unable to effectively treat 
the patient. 
Theoretical Framework 
The Theory of Planned Behavior 
The Theory of Planned Behavior (See Exhibit 2) was created by Icek Azjen as an 
extension to the Theory of Reasoned Action (41).  The Theory of Reasoned Action states 
that an individual is more likely to perform an action if he believes the consequences of 
that action will be positive and if he believes that those who are socially important to him 
also believe the action is positive.  The Theory of Planned Behavior takes this one step 
further in identifying "control beliefs", or the individual’s beliefs about their actual ability 
to perform a given task, as the third key in predicting if an individual is likely to perform 
that task.    
Behavioral Beliefs: 
If a given individual believes that the consequences of taking prohormones are 
positive than he/she is more likely to actually take them.  In this case the individual may 
take into account the negative health outcomes theorized to accompany prohormone use 
and compare that against the perceived positives of increased musculature or improved 
performance.  If the positives outweigh the negatives then a positive "attitude toward the 
behavior" will prevail. 
Normative Beliefs: 
For an individual to use prohormones he/she may think about what other members 
of society, or more specifically his/her social circle will think about the behavior.  If they 
think members of their social group will be pleased about taking these drugs then the 
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normative beliefs would be positive.  Each individual’s beliefs and the ranking of how 
important it is for the subject to comply with those beliefs create the "subjective 
norm."  This is really just the cumulative beliefs of all those the subject feels are 
important and whether they are positive or negative. 
Control Beliefs:  
Control beliefs convey the individual‘s beliefs about whether he or she is actually 
able to complete the task and what factors may help or hinder that ability.  The most 
obvious of these is whether an individual believes there is enough money to purchase the 
prohormones or if there is access to a gym.  Either of these could bolster the subject’s 
intentions or lower them and greatly impact the likelihood of performing the action.  The 
overall belief about both impeding and facilitating factors creates individuals "perceived 
behavioral control”. 
Actual Control: 
While not discussed as part of the decision making process, the subject does need 
to have the actual physical ability or skills to perform the task.  In this case if all 
prohormones were made illegal and destroyed the subject would not be able to actually 
obtain them next week regardless of their planned behavior. 
It is important to remember that these factors do not act alone but in combination 
with each other.  The normative beliefs of a culture could certainly impact the behavioral 
beliefs of an individual just as much as the behavioral beliefs could influence individual 
perception of normative beliefs and the same is true for control beliefs.  This model is not 
so much a progression of steps but an accumulation of factors that can then predict 
individual behavior. 
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Methods 
The Survey 
 The survey instrument was designed to fit the research questions of the study.  
Several focus areas exist within the survey including: demographics, experienced health 
outcomes, details about prohormone use, and beliefs of users about the health care 
system.  Each question was reviewed and discussed by the dissertation committee ending 
with a total of thirty-seven questions being formulated.  After committee review the 
survey was submitted and approved by the Institutional Review Board (IRB) of UNC 
Charlotte and built using SuveyShare TM.  The survey was posted to two prohormone 
discussion forums dedicated to those who use prohormones and posts were placed 
informing the community of what the survey was, what the intentions are, and the 
duration ending on September 8, 2013.  After initial posting the survey was monitored 
and posts made to keep the survey at the top of the discussion forum comments to 
maximize survey visibility to potential participants. 
Proposed methods for each portion of the study 
Paper 1 Methods 
Paper one will used means and frequencies to determine common characteristics 
among prohormone users.  As discussed in the background section there was potential for 
age to impact background characteristics so chi square analysis was used with categorical 
variables.  T-tests were used for continuous variables and chi-square tests for categorical 
variables to identify differences between users who began before the age of thirty and 
those who began after that age.  To gain a more defined picture of how the age of first use 
impacts prohormone use characteristics logistic regression analysis was performed.  The 
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logit model predicted the odds of each characteristic based upon beginning use before the 
age of twenty five. 
Paper 2 Methods 
Adverse events are hypothesized to be common among prohormone users.  Basic 
frequencies and counts were used to find and order outcomes from the most common to 
the least.  All outcomes given were included in a table with the number of users who 
experienced the given outcome.  Means were used to describe the average number of 
outcomes per user, cycles per year and cycles in a lifetime.  All outcomes with two or 
more occurrences were used for further analysis. 
T-tests and chi square analysis were used to assess differences in health outcomes 
between users who use the recommended dosage versus those who use more than 
recommended.  Finally independent multivariate logistic regression were used to estimate 
odds of each outcome while controlling for age and education.  Sensitivity analysis was 
done using a MANOVA including all outcomes simultaneously.  Further analysis were 
included such as the clustering of factors and outcomes associated with those clusters. 
Paper 3 Methods 
The number of users who interact with the health care system and how they 
interact with it will be detailed using how many see a primary care physician, frequency 
of office visits, and averages of beliefs.  These results will then be analyzed by 
comparing users of only prohormones versus those who use both prohormones and AAS 
in t-test and chi-square analysis.  Multinomial logistic regression will be used for scalar 
variables and binary for those with only two levels to compare the same two groups while 
controlling for age and education. 
 
    
 
 
 
CHAPTER 2: DEMOGRAPHICS OF PROHORMONE USERS
 
 
Background 
 
Prohormones are a group of substances chemically similar to anabolic steroids 
that are sold as legal nutritional supplements in the United States.  These substances 
are either anabolic steroids that were created in the mid 1900’s and never released as 
pharmaceuticals or are entirely new substances created from illegal anabolic steroids 
(2).  In either case these substances are not covered under the Drug Enforcement 
Agencies schedule three listing and are therefore legal to be sold as nutritional 
supplements.  Anabolic steroids are known to cause health problems in those who 
abuse them including hyperlipidemia, hypertension, acne, and gynecomastia, as well 
as possible links to heart disease, cancer, and diabetes (4, 30, 42). 
To date, there have been no reports published on the demographics of 
prohormone users despite the associated health concerns. Therefore, assumptions are 
made about prohormone users that derive from the better known demographics of 
AAS users.  Demographics for AAS users show a distinct demographic split 
depending on the age of the subject in question (21, 43).  Because of existing data and 
the ease of new data collection in a school setting, children and adolescents are the 
most studied age groups (18, 19).  From this research it is evident that adolescent 
AAS users commonly participate in sports, are more likely to have body image 
concerns, use other illicit drugs, and miss school more than their non-AAS using 
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peers (Yesalis, Barsukiewicz et al. 1997, Stilger and Yesalis 1999, Yesalis and 
Bahrke 2000, Bachman, O'Malley et al. 2011, Denham 2011). Studies have reported 
disparate findings in terms of racial prevalence and prevalence within socioeconomic 
classes. As a result of these disparate findings these indicators cannot reliably be used 
as a predictive factor at present (44). 
 The demographics of adult AAS users contrast those of adolescent’s.  Of the 
few large studies investigating adult AAS users they tend to be well educated, 
employed, but do not participants of sports activities (24, 25, 43).  Some studies have 
shown that adult AAS users suffer continued body image concerns and most studies 
agree that illicit drug use other than AAS is much higher than non-AAS using peers, 
but whether these data indicate continued illicit drug use or if this is just a leftover 
artifact in the data from when the individuals were of adolescent age is unclear (26).  
It remains largely unclear with little longitudinal data whether the individuals who 
use AAS when they are children remain as low academic and social achievers and are 
entirely separate from what is known about adult users or end up eventually 
becoming the high achievers we see in studies of adults.  
The goal of this study was to describe a prohormone using population in terms 
of their background characteristics and their prohormone use patterns.  With a 
seeming demographic divide depending on the age of the participants being studied 
this paper assessed any demographic differences between those who initiated 
prohormone use before the age of twenty five versus those began use after that age. 
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Methods 
Data 
 The data used in this study was gathered using an online survey.  The survey 
was created by the authors including candidate and committee, approved by the 
institutional review board, and uploaded to the Internet using the SurveyShare
TM
 
survey tool.  The survey link was posted to two online forums dedicated to 
prohormone use.  These forums are portals for users to discuss a wide range of topics, 
including personal experiences, related to prohormone use.  After initial posting, the 
survey was promoted on the forums for a total of two months.  The survey link was 
then posted to Facebook
TM
 on pages for private gyms catering to weightlifting, 
powerlifting, and fitness.  The total convenience sample netted sixty one responses to 
the survey that were used for this analysis. 
Variables 
Background 
Background variables measured in the study include current age, gender, and 
education.  Current age was measured as a categorical variable with categories 
including 18-19, 20-24, 25-29, 30-39, 40-49, along with 50 and above.  Education 
was also measured as a categorical variable with levels of high school only, being 
currently in college, having a vocational degree, associate’s degree, bachelor’s 
degree, and master’s degree or higher.  Gender was collected as a binary variable with 
male and female. 
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Prohormone Use Characteristics 
  Measured prohormone use characteristics include age at first use, number of 
prohormone cycles ever used, prohormone cycles per year, dosage taken during the 
last cycle, number of substances used in the last cycle, and reasons for using.  Age at 
first use and number of substances taken in the last cycle were both measured as 
continuous variables.  Number of prohormone cycles ever used and use per year were 
both measured as categorical variables including levels of one, two, three, four, and 
more than four.  Dosage taken was measured as a categorical variable of less than 
recommended, exactly recommended, and more than recommended.  Reasons for 
initiating use include weight lifting sport, non-weight lifting sport, to look better, to 
be stronger, and to help in my job.   
Study 
Means and frequencies were used to determine common characteristics among 
prohormone users.  As discussed in the background section there is potential for age 
to impact background characteristic.  T-tests were used for continuous variables and 
chi-square tests for categorical variables to identify differences between users who 
began before the age of twenty five and those who began after that age.  Categorical 
variables were collapsed into groups when cell sizes were too small to allow for 
meaningful analysis.  Missing data was largely censored out of the study with only 
four values being imputed with averages for the relevant age and use characteristics 
of the user.   
To describe the demographics of how age and education levels impact 
prohormone use patterns, multinomial and binomial logistic regression were used to 
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assess the effect of having initiated used before the age of twenty five of several use 
patterns.  Results were expressed in odds ratios with confidence intervals and p-
values. 
Results 
Current age at time of the survey ranged from eighteen to more than fifty 
years old with a median age category of twenty-four to twenty-nine years old.  
Education also varied but is far above what is considered average with more than 
forty-six percent holding a bachelor’s degree or higher (Table 1)(45).  Prohormone 
use patterns are further described in Table 2.  Average age of first use, otherwise 
known as a cycle, was 26.4 years of age, but with a broad standard deviation at 7.07 
years.  The average number of cycles per year is 1.93 (SD) with lifetime usage 
ranging between once and 4 or more times.  The most common duration of cycles was 
six weeks with an average of 1.85 (SD) prohormones taken in an average cycle.  The 
most frequently reported reason for prohormone use was to ‘look better’ (49.18% ± 
SD), but improving strength and performance in weight lifting related sports also 
make up a large portion of the reported reasons for prohormone use (22.95% ± SD 
and 24.59% ± SD respectively). 
 Assessing differences between older and younger prohormone users revealed 
differences in the averages shown in tables one and two (see Table 3).  After dividing 
the population into those who began using prohormones before 25 years of age and 
those who began after 25 years of age, understandably created significant differences 
in current age, but also created a significant difference in age at first use (p = <0.01; 
Table 3).  Additional significant differences between age groups included reasons for 
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initiating use (p=<0.01, Table 3) and the number of prohormone cycles used per year 
(p=<0.01, Table 3).  Older individuals were more likely to use prohormones to 
enhance physical appearance while the younger users reported more interest in 
strength gains, as well as improved performance in weightlifting related sports (e.g. 
bodybuilding).  Younger respondents were more likely to use prohormones in two 
cycles per year, while older users are more likely to only use one cycle per year.  
Planning to use prohormones again was also significant (p= 0.02), but as only two 
individuals in the entire sample responded that they were not planning to use 
prohormones again the variable had to be dropped from further analysis.  All other 
variables included in chi-square analysis were not significant. 
 In multivariate analysis the two factors that were significant in univariate 
analysis, those being cycles taken per year and the reasons for use, remained so while 
controlling for the education of the individual (Table 4).  Individuals who started 
using prohormones at an earlier age are 5.04 times (p = 0.01, CI = 1.44-17.68) more 
likely to complete two prohormone cycles a year and 8.96 times (p = 0.01, CI = 1.69-
47.51) more likely to complete three or more cycles per year compared to their older 
counterparts.  The reported reasons for using prohormones also differed with younger 
initiators being less likely to use prohormones to improve perceived physical 
appearance compared to older respondents (OR = 0.24, CI = 0.06-0.87).  
Discussion 
 This is the first study to report demographic information about prohormone 
use patterns and characteristics of prohormone users.  As an emerging group of 
performance enhancing drug users there are a couple of reasons that society should 
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take note.  First, this group has the potential to experience all of the negative health 
consequences that are currently associated with AAS.  Compounding this is the 
absence of information about the population prevalence of this group.  With current 
forum enrollment seen at approximately fifty five thousand individuals and no 
estimate as to the number of forums in existence the population has the potential to be 
large.  Any large group of individuals with serious health implications could have a 
negative impact on the health care system.  Secondly our understanding of this group 
can help us to learn the actual health impacts associated with these substances and 
positively focus any health interventions necessary.  Of note is the reluctance of 
performance enhancing drug users to talk about how they use substances.  The 
building of a background profile of a sample of prohormone users can set the 
groundwork for future studies. 
The results of this study suggest that younger prohormone users complete 
more cycles per year and reported a greater interest in sports performance and 
perceived physical appearance.  This difference between older and younger 
prohormone users shows a contrast within the population that could be explained by 
two primary factors.  First, known prohormone availability began in the early 1990’s 
and some users may have started using these substances prior to this if they had been 
available.  Moreover, it is possible that when current older users were younger, they 
may have used prohormones for similar reasons as those reported by current younger 
users (e.g. physical performance) had these substances been available.  This second 
point is merely speculation, as the data does not exist for the prohormone population 
or an older anabolic steroid using population.     
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Factors that were not statistically significant may still help to improve 
understanding of prohormone user demographics.  Overall, the respondents in this 
study had achieved an above average level of education with 47.55% of the sample 
with a bachelor’s degree or higher, well above the 31.4% considered average for 
males over the age of twenty five in the United States population (45).  Ninety 
percent of users were between the ages of twenty and forty completed at least one 
prohormone cycle per year with an average of two substances per cycle.  Currently 
we have no idea of the cumulative effect of taking more than one prohormone at the 
same time.  Even in the AAS population it is known to be common but our 
understanding is lacking.  As a testosterone related substance polypharmacy is 
considered to be a negative health implication.  Fifty nine percent of users had also 
taken anabolic steroids within the last calendar year.  This implies that either 
prohormones are substances taken by anabolic steroid users while not on steroid 
cycle, taken by anabolic steroid users while on cycle possibly to improve the effects 
of a cycle, or are themselves a gateway into anabolic steroid use.  All three options 
are plausible and may occur simultaneously within different segments of a 
prohormone using population. 
 The limitations of this study are mainly present within the study design.  As a 
population that is difficult to study, the forum based convenience sample was the only 
plausible option to reach a larger population.  The sample cannot therefore be used to 
make assumptions about the population in general.  Another limitation of this study 
was the low statistical power and as stated previously, post hoc power analysis 
indicated that this study could only detect differences greater than thirty percent as 
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significant.  While this was enough power to detect differences when the sample was 
very evenly distributed as with age at first use, other differences that were more 
skewed such as recommending prohormones to a friend may require larger sample 
sizes before effective assessments can be made. 
 The strength of this study is the population investigated.  Very little data exists 
pertaining to prohormone users and the data that does exist is usually limited to 
individual cases (27).  This study has described a prohormone using population on a 
larger scale than previously reported.  The information provided by this study 
facilitates decision-making with regard to future hypotheses and study design.  For 
example utilizing online forums to elicit information from prohormone users is an 
effective method.  Furthermore there is some evidence of a divide within older and 
younger users for reasons of use and how prohormones are used that needs further 
exploration. 
 This was a pilot study that investigated a research area with a paucity of data.  
While it presents important information about the demographics of prohormone users, 
who may experience significant health risks associated with their use of these 
substances, larger sample size studies are now required to describe these individuals 
and the potential implications of prohormone use. 
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Table 1: The profile of the prohormone user (n=61) 
 Frequency/Mean Percent/SD 
Gender Male 100 
Age   
18-19 1 1.64 
20-24 17 27.87% 
25-29 21 34.43% 
30-39 17 27.87% 
40-49 4 6.56% 
50+ 1 1.64% 
Education   
High School or less 2 3.28% 
Vocational 5 8.20% 
Associates 12 19.67% 
Currently in College 13 21.31% 
4 Year College 20 32.79% 
Masters or higher 9 14.76% 
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Table 2: Prohormone use characteristics 
 Frequency/ Mean Percent/ SD 
Age at first cycle 26.40 7.07 
Cycles per year 1.93 1.06 
Cycle duration   
Four weeks or less 15 24.59% 
Six weeks 36 59.02% 
Two Months or more 10 16.39% 
Number of prohormones taken in 
last cycle 
1.85 0.66 
Cycles completed in lifetime   
1 16 26.23% 
2 7 11.48% 
3 12 19.67% 
4 15 24.59% 
More than four 11 18.03% 
Reason for initiating use 2.93 1.64 
Weight lifting sport (powerlifting, 
bodybuilding) 
15 24.59% 
To look better 30 49.18% 
To be stronger 14 22.95% 
Help me in my job 1 1.64% 
Any other sport 1 1.64% 
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Table 3: Differences between older and younger users (began <25, began >=25) 
 <25 >25 P 
Age of first use 21.03 (1.97) 32.00 (6.22) .00 
Current Age   .00 
18-19 1 0  
20-24 16 1  
25-29 12 9  
30-39 1 16  
40-49 0 4  
50+ 0 1  
Education   0.28 
High School  10 5  
Vocational/Associates 8 9  
College Graduate or more 12 17  
Cycles per Year   0.01 
1 6 18  
2 16 10  
More than two 8 3  
Cycle duration   0.98 
Four weeks or less 7 8  
Six weeks 18 18  
More than six weeks 5 5  
Dosage   0.90 
Recommended or less 15 16  
More than recommended 15 15  
Cycles completed in lifetime   0.48 
1 6 10  
2 5 2  
3 5 7  
4 7 8  
More than four 7 4  
Number  of prohormones 
taken in the last cycle 
  0.95 
1 9 9  
2 17 17  
More than two 4 5  
Reason for initiating use   0.04 
Look better 10 20  
Improve strength 8 6  
Other 12 5  
Also taken AAS in the past 
year 
  0.88 
Yes 12 13  
No 18 18  
Going to use prohormones 
again 
  0.02 
Yes 30 29  
No 0 2  
Recommend prohormones to 
a friend 
  0.25 
Yes 28 26  
No 2 5  
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Table 4: Prohormone use factors based on age starting before twenty five and controlling for education 
 OR* CI** P-value 
Cycles Per Year1    
2 5.04 1.44-17.68 0.01 
Three or more 8.96 1.69-47.51 0.01 
Cycle Duration2    
Six weeks 1.15 0.34-3.93 0.82 
More than six weeks 0.80 0.15-4.38 0.79 
Cycles Completed in 
lifetime3 
   
2 4.81 0.65-35.71 0.12 
3 1.49 0.30-7.44 0.62 
4 2.12 0.45-9.95 0.34 
Five or more 4.33 0.78-24.02 0.09 
Number of PH taken in the 
last cycle4 
   
2 1.01 0.31-3.23 0.99 
Three or more 0.96 0.18-4.96 0.96 
Reason for using5    
To look better 0.24 0.06-0.87 0.03 
Other 0.56 0.13-2.53 0.45 
Recommend prohormones to 
a friend 
3.75 0.60-23.42 0.16 
Taking more than the 
recommended dose 
1.11 0.39-3.09 0.84 
Also taken AAS in the last 
year 
0.806 0.28-2.32 0.69 
*OR= Odds Ratio, **CI= Confidence Intervals, 1= referent category one cycle per year, 2= referent category cycle 
duration of four weeks or less, 3= referent category one cycle in lifetime, 4= referent category one PH in last cycle, 
5= referent category wants to be stronge
 
 
 
 
 
 
CHAPTER 3: SIDE EFFECTS OF PROHORMONE USE
 
 
Background 
Adverse side effects resulting from performance enhancing drug use has been 
the primary focus of research on this topic since nonprescription use began.  
Investigating the health effects of using a performance enhancing substance improves 
understanding of the negative consequences associated with it.  A limited amount of 
research has been conducted specifically to investigate prohormone use.  In two case 
studies the prohormone Methasteron (Superdrol) was linked to advanced liver 
damage (27, 46).  One of the two studies detailed a college student’s hospitalization 
after a little more than a month of using the substance (27).  To compensate for the 
paucity of information regarding side effects of prohormone use, similar studies on 
the health effects of anabolic steroids (AAS) are helpful as they are chemically 
closely related. 
 The scope of adverse side effects associated with AAS has been controversial 
for decades, but some AAS adverse side effects are well accepted.  These established 
adverse side effects include, but are not limited to, acne, hair loss, increased blood 
pressure, and hyperlipidemia, increased feelings of anger, liver damage, elevated 
prostate specific antigen (PSA) levels and erectile dysfunction(1, 3, 4, 13, 29-33).  
These outcomes are considered short-term side effects meaning they would likely 
return to normal within approximately six months to a year after cessation(1).  The 
percentage of individuals who experience adverse side effects is unclear and with 
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more than one hundred different AAS products available, the combination of adverse 
side effects may be specific to the AAS used.  This substance specific potential for 
outcome may also be associated with prohormones, but this is currently not studied. 
Longer-term outcomes are more challenging to measure and evidence for 
specific long-term health outcomes in association with AAS use is lacking. The 
exception to this rule is gynecomastia, breast growth in men, which is known to occur 
with AAS use in some individuals (29).  Other potential long-term effects associated 
with AAS use include: heart disease, cancer, stroke and permanent prostate damage 
(32, 34-37).  While little research associates the effects of different dosage, 
pharmacological principles suggest that adverse effects would increase with increased 
dosages also known as a “dose response” (47).  Lack of research regarding outcomes 
found at each dose may have to do with the doses that most AAS users take which far 
exceed pharmacologic doses and are highly variable between users (24).   The 
association of these principles and prohormones can only be guessed at with no 
research on the topic.  The purpose of this study was to assess associations between 
prohormone use and short-term and as many of the long-term health outcomes as 
possible.  Prohormone related health outcomes will then compare those taking the 
manufacturer recommended dose and those taking higher doses.  Finally, adverse side 
effect risk will be compared between those who are seen to have multiple risk factors 
versus just one. 
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Methods 
Survey instrument 
 The instrument used to collect data for this study was an online survey 
focused on prohormone users.  The survey included questions about prohormone use, 
demographics, outcomes, health care beliefs, and post cycle therapies.  Two online 
forums that focus on prohormone use were selected.  The survey was posted to these 
for a period of two months with continual updates by the research team to ensure 
visibility within the forum.  For an additional month the survey was posted to the 
Facebook
TM
 page of a privately owned fitness company whose owners are involved in 
the bodybuilding and powerlifting communities.  After a total period of three months 
data collection ceased, the results were downloaded for analysis. 
Data analysis 
An overall description of the population included gender, age, and educational 
status of the prohormone users who responded to the survey.  Adverse side effects are 
hypothesized to be common among prohormone users.  Basic frequencies and counts 
were used to find and order outcomes from the most common to the least.  All side 
effects reported with at least two occurrences were included in a table with the 
number of users who experienced the effect and the percentage of the population 
involved.  Means and standard deviations were used to describe the average number 
of effects per user, cycles per year, number of substances taken in the last cycle, and 
cycles in a lifetime.   
Prohormone users were divided between those who took the recommended 
dose or less and then who took above the recommended dose.  Independent 
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multivariate logistic regressions were used to estimate odds of each effect occurring 
as a result of increased dose while controlling for age and education.  The association 
of side effects experienced on beliefs about the commonality of effects in general will 
be tested using Pearson correlation tests.  The population will be divided into those 
who experienced a number of effects above the average, experienced the average, and 
then those who experienced none.  These will be correlated with answers to a survey 
questions asking on average how common are side effects within the population.  
Finally, the impact of being at multiple risks of increased side effects 
simultaneously was assessed.  Other than dose, risk factors included the number of 
prohormones taken in a given cycle, the number of cycles per year, cycle duration, 
and having taken AAS in the last year.  To be considered at risk for the number of 
prohormones taken in a cycle only those who took above the average number of 
substances were used.  Similarly, those who completed more than the average number 
of cycles per year will be considered at risk and the same was used for duration.  If 
the individual indicated that they had taken AAS in the last year they were 
automatically considered at risk.  A Pearson correlation test was used on the risk 
factors to test for collinearity.  The above four risk factors were combined with 
dosage to create a pool of individuals experiencing multiple risks.  These individuals 
then were compared to their single risk peers, associating risk with the chance of 
experiencing more than the average number of side effects. 
Results 
Sixty-five observations were used for overall analysis.  Population 
characteristics show the responders were 100% male, with an age range of eighteen to 
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the lower fifties with a concentration of individuals in their twenties (64.62%, Table 
one).  The individuals are well educated with 46.16% having received a bachelor’s 
degree or more and all individuals having at least a high school diploma.  
Prohormone use characteristics show an average of 1.84 prohormones taken per cycle 
with a standard deviation (SD) of 0.67 and 1.80 cycles per year (SD=0.75).  Of the 
users, 49.23% (n=32) consumed more than the manufacturer recommended dosage 
and 40.00% (n=26) percent have also taken anabolic steroids within the last year. 
Side effects experienced by two or more users included eighteen different 
effects along with eight individuals who have never experienced a side effect (Table 
two).  The most common reported side effect was “Feeling sluggish” with 53.85% 
(n=35) of users admitting they had experienced this side effects.  Acne and increased 
aggression were equally the second most common with twenty-four individuals or 
36.93% of the population reported experiencing one or the other.  Headaches, 
cholesterol issue, and hair loss were the next three most common effects with 
33.85%, 18.46%, and 15.38% respectively.  All other side effects were experienced 
by less than ten percent of the population and night sweats were the least common 
side effect experienced (only two individuals or 3.08%) and were not included in 
further analyses. 
There was a significant, positive correlation between experiencing objective 
adverse effects and beliefs about the frequency of side effects experienced (R=0.26, 
p=0.04, Table three).  There was not a significant impact of using more than the 
recommended dosage on the chances of experiencing a given side effect (Table four).  
The test of collinearity indicated that AAS use and cycle duration were highly 
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correlated with the number of substances per stack and therefore they were dropped 
from analysis.  Multiple risk analysis did show an association between experiencing 
multiple risks and experiencing an above average number of side effects. (OR= 8.45, 
CI= 1.53-46.99)(Table five).  When broken down into combinations of dosage and 
other risks individually no significant difference was seen. . 
Discussion 
This study has established a range of side effects experienced by prohormone 
users.  Overall the effects are negative and included sluggishness, acne, and 
aggression as the most common.  If studies on anabolic steroids can be used as an 
example of duration of the effects listed above, they are likely short-term and resolve 
within six months of cessation of prohormone use, with the exception of 
gynecomastia which was uncommon in the sample(4).  However, it is important to 
note that not every side effect is negative since three individuals stated an increased 
sense of “wellbeing.”  Because of the limited research done on prohormones users, 
we are the first to report this positive effect, which may be specific to prohormone 
use.  Positive effects found in AAS research are rare and most studies have involved 
qualitative research, interviewing users (39). 
The correlation analysis adds information about the mindset of users based on 
their own experiences. Previous anabolic steroid research has reported that adolescent 
users do not believe the information they receive in school about the side effects of 
use (40).  This is further confirmed with similar lack of belief present in adult AAS 
users (39).  This sample indicates the impact of experiencing overt side effects 
affected user’s beliefs about the commonality of side effects.  Those individuals who 
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had never experienced a side effect believed that they were uncommon in the 
prohormone using population (R=0.26, p=0.04).  Those who experienced more than 
the average number of side effects were not significantly correlated with the belief 
that they are common (R=0.17, P=0.16).  These new findings are in line with 
previous research on AAS users as individuals who had experienced more than the 
average number of side effects still disbelieved that side effects were common among 
prohormone users in general(39). 
Dose-response relationships between dose taken and effects, both positive and 
negative, are expected among anabolic hormone supplementation (48).  In this 
analysis dose-response effects were not found in association with side effects.  This 
finding may be explained by two factors.  First, as previously stated this is a pilot 
study and therefore had a lack of statistical power.  For example, the effect of hair 
loss was reported less in those who used more than the recommended dose (OR= 
0.19, p=0.06), this effect with a p-value close to significance may have been 
improved with a larger sample.  Second, it is unclear how the recommended doses 
were originally established.  For many of these substances drug trials regarding 
substance effectiveness and safety have not been conducted.  It is possible that 
recommended doses are sufficiently high to elicit the effects reported here and there 
are no additional effects experienced when more than recommended is taken.  It is 
also important to note that the desired effect of increased muscle mass was not 
questioned and that there is no data regarding doses required for muscular outcomes.  
The multiple risk analysis provided several important pieces of information.  First, 
those individuals who use prohormones in a manner that they experience multiple 
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simultaneous risk factors are at increased odds for experiencing more than the 
average number of side effects (Table 5).  Second, those individuals who also use 
AAS are significantly correlated with other high risk factors including more 
substances per cycle and more cycles per year.  These two pieces information provide 
an important point for future research into this population indicating a special need to 
focus on AAS-prohormone dual users. 
The primary limitation of this study was the lack of statistical power.  With so 
many effects being experienced and some with small numbers of individuals 
experiencing them, comprehensive analysis of the sample was challenging.  As a pilot 
study into a new area of research, the design of this study is a convenience sample 
and therefore no generalizations about prohormone users were possible.  This design 
limitation only allowed for descriptive analysis of the observed population subset. 
The strengths of this study are that it provides a framework for future 
research.  In previous research it has been cited that users of performance enhancing 
drugs are difficult to study.  These individuals tend to be secretive and reluctant to 
discuss any detail regarding their drug use, therefore any information gained is 
helpful.  The list of effects reported here will help facilitate future research focusing 
on degrees of severity within effects as opposed to establishing that they exist.  Most 
importantly is the implication for further research on the population experiencing 
multiple risk factors simultaneously as these individuals may be more susceptible to 
adverse side effects. 
Prohormones remain an understudied and little understood form of nutritional 
supplement, but their use may lead to significant adverse health outcomes.  This study 
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was a pilot that investigated side effects experienced by prohormone users and 
associations with potential risk factors, such as taking more than the recommended 
dose.  Clearly more research is needed to understand the population in more detail. 
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Table 5:  Descriptive 
 Frequency/ Mean Percent/SD* 
Gender   
Male 65 100% 
Age   
18-19 1 1.54% 
20-24 20 30.77% 
25-29 22 33.85% 
30-39 17 26.15% 
40-49 4 6.15% 
50-54 1 1.54% 
Education   
High School or less 2 3.08% 
Vocational 5 7.69% 
Associates 13 20.00% 
Currently in College 15 23.08% 
Bachelors 21 32.31% 
Masters or higher 9 13.85% 
Average number of 
Prohormones taken in a cycle 
1.84 0.67* 
Dosage above recommended 32 49.23% 
Average number of cycles 
per year 
1.80 0.75* 
How common are side effects   
Very common 14 22.22% 
Somewhat common 35 55.56% 
Not common 14 22.22% 
Also an AAS user 26 40.00% 
*SD-Standard Deviation  
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Table 6: Side Effects Observed 
 Number observed Percent of users reporting 
this outcome/ SD* 
Total Population 65  
Self-evaluated outcomes   
Hair loss 10 15.38% 
Acne 24 36.92% 
Feeling “sluggish” 35 53.85% 
Cholesterol issues 12 18.46% 
High blood pressure 6 9.23% 
Chest pain 4 6.15% 
More Aggression 24 36.92% 
Gynecomastia 4 6.15% 
Chest tenderness 9 13.85% 
Back Pain 4 6.15% 
Headaches 22 33.85% 
Decreased libido 3 4.62% 
Night sweats** 2 3.08% 
Overall sense of “wellbeing” 3 4.62% 
Never experienced a side 
effect 
8 12.31% 
Average number of side 
effects 
2.49 1.61* 
Diagnosed conditions since 
prohormone use began 
  
Diagnosed with high blood 
pressure 
8 12.31% 
Diagnosed with high 
cholesterol 
4 6.15% 
*Standard Deviation 
**Too small for further analysis 
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Table 7: Correlations of Beliefs and Experienced Side Effects 
 Correlation P-value 
Experiencing an above 
average number of side 
effects and believing side 
effects are very common 
 
0.17 0.16 
Having never experienced a 
side effect and believing side 
effects are not common 
0.26 0.04 
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Table 8: Odds of experiencing side effects based on above recommended dosage
1 
 
 OR * P-value CI** 
Self-evaluated outcomes    
Hair loss 0.19 0.06 0.03-1.04 
Acne 0.47 0.07 0.17-1.35 
Feeling “sluggish” 0.93 0.88 0.35-2.47 
Cholesterol issues 0.45 0.24 0.12-1.70 
High blood pressure 2.52 0.34 0.40-15.85 
Chest pain 1.02 0.99 0.13-7.84 
More Aggression 0.72 0.56 0.24-2.16 
Gynecomastia 1.13 0.91 0.14-8.87 
Chest tenderness 2.30 0.28 0.51-10.44 
Headaches 1.88 0.24 0.66-5.39 
Reduced libido 0.46 0.54 0.04-5.70 
Back Pain 1.04 0.97 0.13-8.11 
Overall sense of 
“wellbeing”  
2.40 0.50 0.19-30.21 
Never experienced a 
side effect 
1.06 0.94 0.24-4.71 
Diagnosed:    
High blood pressure 0.99 0.99 0.19-5.07 
High cholesterol 3.12 0.35 0.29-33.04 
1 
Controlled for age and education 
*OR- Odds Ratio 
**CI-Confidence Interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
Table 9: Multiple risk factor analysis of experiencing a higher than average number (≥3) of 
self-evaluated outcomes 
 OR P-value CI 
Above recommended 
Dose 
 
Any risk combined 
with above 
recommended dose 
 
1.59 
 
 
 
8.45 
0.37 
 
 
 
0.02 
0.58-4.34 
 
 
 
1.52-46.99 
Combined with    
Three or more 
prohormones per stack 
1.90 0.44 0.38-9.67 
 
Three or more cycles per 
year 
 
4.57 
 
0.09 
 
0.78-26.80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4: HEALTH CARE BELIEFS OF PROHORMONE USERS
 
 
Background 
Patient beliefs about the credibility of information provided by physicians 
have been studied for many years, as it is an integral part of health care delivery (49, 
50).  Of the many studies and measurement scales in existence to assess patient-
provider interactions there appear to be differences in patient and health care provider 
interactions based upon the gender, race, age, and the physical appearance of the 
physician (51).  There are also differences based upon the race, gender, and age 
demographics of the patient (52).  Some evidence suggests that there are also 
differences based upon the health behaviors of the patient such as drug use and that 
will be the focus of this study (53).   
Prohormones are substances chemically similar to anabolic-androgenic 
steroids (AAS) or are legal substances that break down into anabolic steroids (2).  In 
the United States these substances are considered nutritional supplements, although 
some have made the transition to being legally considered AAS such as 
androstenedione (7).  Currently there is little information about these substances in 
terms of the people who use them, their pharmacokinetics and pharmacodynamics, 
how many types are available, and the experiences of those who use them.   
      Since prohormones are similar to AAS, it is possible that users experience 
similar negative side effects.  If so, prohormone users may need medical attention as a 
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result of their prohormone use (1, 11, 34).  Currently, interactions between 
prohormone users and physicians, and what their perceptions are of the physician’s 
knowledge with regard to prohormones have not been described.   
Pope et al (2004) found little difference in beliefs about health care provider 
credibility between AAS users and their non-using, weightlifting peers (38).  The 
authors inquired about general health, illicit drug use, smoking, and many others with 
no differences found except for beliefs about nutritional supplements and AAS.  The 
AAS users believed less of a physician’s advice about AAS than their non-using 
peers and placed more credibility on information from “underground publications” 
dealing with AAS use.  This lack of acceptance regarding physician provided 
information was not unexpected as previous reports have observed that adolescents 
who use AAS do not believe the information they receive about the drugs in school 
(23, 39) (40).  Pope et al also reported that a large number of AAS users do not 
discuss their use with their physicians, making it difficult to correctly diagnose and 
treat a set of symptoms (38).  If a similar scenario exists in prohormone users, the 
implications for the medical community may include incorrect diagnosis of symptoms 
and potentially harmful unnecessary treatment to the patient.  This study assed if 
prohormone users interact with the health care system, frequency of doing so, their 
perceptions about the knowledge of physicians, and whether they believe physician 
provided accurate information. 
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Methods 
Survey 
 To obtain information about this population, a convenience sample survey 
was created.  Questions within the survey inquired about basic demographics, use 
patterns, health care beliefs, and health outcomes.  The survey was posted to two 
online forums dedicated to prohormone use for a period of two months and the 
Facebook page of a privately owned gym for one month.  Data was then downloaded 
via excel spreadsheets and stored for further analysis. 
Data 
All statistical analysis was completed using SAS 9.3 (Cary, NC).  Basic 
demographics were tabulated into table.  Two more tables divide beliefs about 
physicians in general and beliefs about physicians the users actually interact with.  
Table 2 outlines the beliefs of prohormone users about physicians at large, meaning 
not their own physician.  Table 3 asks the same questions about how knowledgeable 
and accurate the information is, but restricted to the physician that the individual 
actually interacts with.  All data is presented as frequencies with corresponding 
percentages. 
Univariate statistical analysis was used to test the differences in beliefs based 
on being a prohormones user only and being a prohormone user who also uses AAS.  
As all variables tested are categorical in nature chi-square tests will be used for all.  In 
some cases categories are collapsed to allow for meaningful analysis.  Finally, 
multivariate statistical analysis is done using logistic regression to control for age and 
education along with giving meaningful effect measures in the form of odds ratios. 
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Results 
 A total of sixty-one responses were used for analysis.  67.22% of the 
population held at least an associate’s degree (Table 1).  Ages of individuals are 
widely spread with the youngest being in the eighteen to nineteen age group and the 
oldest in the fifty plus age group.  The vast majority of individuals (90.17%) are 
currently between twenty and forty years of age.  Forty-eight of the users have been 
to see a physician in relation to prohormone use (78.69%) and twenty five (40.98%) 
have also used AAS in the last year. 
 Beliefs about physicians in general are reported in table 2.  65.57% of the 
sample had gone to see a physician at least once a year with an additional 24.59% 
who say they only go when they are sick.  The remainder of the group goes every 
other year or less (6.56%) or never (3.28%).  A majority of those sampled (40.98%) 
are not comfortable speaking to a physician in general about a prohormones, 36.07% 
indicate that they are comfortable and 22.95% say they are somewhat comfortable.  
When asked about the knowledge of physicians with regards to prohormones, only 
one individual stated that physicians are very knowledgeable.  The other individuals 
are exactly divided with twenty stating physicians know a little, twenty stating they 
know nothing, and the last twenty stating they, the respondents, did not know how 
knowledgeable physicians are.  Finally, beliefs about the accuracy of information that 
physicians give in regards to prohormones were collected.  No individuals believed 
that physicians gave very accurate information and only fourteen (22.95%) believe 
that physicians give somewhat accurate information.  Sixteen (26.23%) individuals 
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believed that physicians give false information about prohormones and the other 
thirty-one (50.82%) state that the physicians give no information. 
 Prohormone user’s beliefs about private physicians contrasted that of 
physicians in general with four respondents (6.56%) indicating that their physician is 
very knowledgeable about prohormones and an additional ten (16.39%) respondents 
stating their physician knows a little about prohormones (Table 3).  Thirteen 
individuals (21.31%) stated their physician knows nothing about prohormones and 
thirty-two more (52.46%) stated they do not know how knowledgeable their 
physician is.  This leaves the final two individuals (3.28%) who stated they do not 
have a physician.  In regards to the accuracy of the information given by the user’s 
physician the responses were again different from physicians in general.  Four 
individuals (6.56%) stated their physicians give very accurate information, nine 
(14.75%) stated their physicians gave somewhat accurate information, and four 
(6.56%) more indicate their physicians gave false information.  Forty-two (68.85%) 
individuals stated their physicians gave no information and the final two individuals 
(3.28%) that do not have physicians. 
After separating observations into those who only use prohormones and those 
who use prohormones in combination with anabolic steroids, chi-square analysis 
revealed one significant difference.  Our data suggest that in this sample prohormone 
only users think differently about the accuracy of information physicians in general 
provide, since they are significantly more likely to state that physicians give no 
information about prohormones (P = 0.05; Table 4).  Significance was not maintained 
after multivariate logistic regression, controlling for age and education, but only 
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slightly with p-value of 0.06 (OR=2.93, CI=0.96-9.07, Table 5).  No other differences 
between prohormone only and prohormone-AAS combination users were significant 
with either chi-square or logistic regression analysis. 
Discussion 
The purpose of this study was to determine the characteristics and beliefs of 
prohormone users with regards to health care and the picture painted by the data is 
bleak.  Of the total population, 78.69% claimed to have interacted with a physician in 
relation to their prohormone use, but only 22.95% of individuals believed the 
information physicians give about prohormones is at least somewhat true.  More 
startling is that no respondents believed physicians in general give very accurate 
information and an additional 26.23% believe physicians give false information.  
Interestingly, there were differences between beliefs about physicians in general and 
those about the physicians that the users actually saw.  A possible explanation for this 
difference is the relationship developed between the physician and the user.  
Somehow amidst these interactions, particular physicians have conveyed topic 
understanding with regard to prohormones. 
An overall lack of difference between those who use exclusively prohormones 
and those who use both prohormones and AAS is also noteworthy.  With 40.98% of 
prohormone users in the sample also taking AAS there is some overlap between the 
two classes of substances.  Prohormone users may be less likely to interact with 
physician and when they do interact were less likely to accept the information given.  
As there was no difference in the mean age of the two groups, it is possible there is 
another explanatory factor unmeasured.   Perhaps prohormone use leads to AAS use 
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or prohormone users are simply unwilling to risk breaking the law and so use a legal 
alternative.  Further studies are warranted to explore these potentially important 
characteristics of the two groups.   
The apparent belief system of prohormone users investigated in this study 
may lead to complications for physicians and the health care system.  Previous work 
on AAS use suggests significant side effects result and we can speculate that similar 
outcomes are associated with prohormones.  If such a high percentage of individuals 
are interacting with physicians in response to prohormone use and only 36.07% are 
actually comfortable speaking to a physician about their use, a physician may be 
presented with a set of symptoms and not enough information to properly diagnose 
the condition.  This lack of open communication could lead to costly, unnecessary 
tests and procedures as a physician attempts to identify causation of the presented 
symptoms. 
The data seen here suggests that health care professionals need to 
communicate their knowledge about this topic better to their patients.  This would 
require a certain amount of patient profiling on the part of the physician, but there are 
certain side effects associated with AAS and potentially prohormones that are 
uncommon with other conditions, such as gynecomastia and abrupt hair loss (4).  
Being able to identify these potential indicators of AAS and/or prohormone use may 
require further education on the physician’s part, especially since some physicians 
feel uncomfortable dealing with illicit drug use (54).  From a public health 
perspective there is a need to better understand these substances and then 
communicate current knowledge about these substances. 
47 
The limitations of this study are in its exploratory nature, sample size, and 
generalizability.  As previously stated this is a pilot study and one of the first in an 
understudied area.  Not having a great deal of background data to inform the survey 
questions means that helpful indicators were seen retrospectively but not measured 
such as why some individuals do not use AAS while others do.  Moreover, sixty-one 
usable responses were gathered for this study and when this was further divided into 
categories there is a lack of statistical power.  This means that actual differences may 
have gone unmeasured.  A lack of generalizability is due to the convenience sample 
design.  Other designs such as including a component of randomization were not 
deemed practical for a pilot study, but may be used in further research. 
The strength of this study is in the base information gained.  This group of 
individuals has thus far remained unstudied and this project has identified important 
characteristics about them along with how they interact with physicians.  Trust and 
open communication between a patient and their physician is a critical part of 
successful health interventions.  This study has identified that, with this sample, trust 
regarding physician knowledge and accuracy is limited.  If in further studies it is seen 
that this lack of trust is widespread throughout the prohormone using population, then 
educational interventions may be needed for both the public and physicians. 
Prohormones are a class of nutritional supplements, the use of which may lead 
to similar health problems as AAS and this has been largely overlooked.  This study 
was the first to assess the beliefs of these individuals by describing a subset of the 
population.  Further large-scale analyses need to be done to fully understand this 
population, their experiences, and how they interact with the health care system. 
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Table 10: Demographics 
 Frequency Percent 
Total population 61 100.00% 
Education   
High School or GED 2 3.28% 
Vocational School 5 8.20% 
Associates Degree 12 19.67% 
In College 13 21.31% 
Bachelor’s degree 20 32.79% 
Master’s degree or higher 9 14.76% 
Age   
18-19 1 1.64% 
20-24 17 27.87% 
25-29 21 34.43% 
30-39 17 27.87% 
40-49 4 6.56% 
50+ 1 1.64% 
Also an anabolic steroid users   
Yes 25 40.98% 
No 36 59.02% 
Have been to a physician in 
response to prohormone use 
  
Yes 48 78.69% 
No 5 8.20% 
Did not answer 8 13.11% 
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Table 11: Beliefs of this prohormone using population about physicians in general 
 Frequency Percent 
Going to the physician   
More than once a year 26 42.62% 
Once a year 14 22.95% 
Every other year or less 2 3.28% 
Less than every other year 2 3.28% 
Only when I am sick 15 24.59% 
Never 2 3.28% 
Comfortable speaking to a 
physician about PH 
  
Yes 22 36.07% 
Somewhat 14 22.95% 
No 25 40.98% 
How much do doctors in 
general know about PH 
  
Very knowledgeable 1 1.64% 
Know a little 20 32.79% 
Know nothing 20 32.79% 
I do not know 20 32.79% 
How accurate or true is the 
information doctors in 
general give about PH 
  
Very accurate 0 0.00% 
Somewhat accurate 14 22.95% 
Gives false information 16 26.23% 
Gives no information 31 50.82% 
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Table 12: Beliefs about personal physicians 
 Frequency Percent 
How knowledgeable is my 
personal physician about 
prohormones 
  
Very knowledgeable 4 6.56% 
Knows a little 10 16.39% 
Knows nothing 13 21.31% 
I don’t know 32 52.46% 
I do not have a physician 2 3.28% 
How accurate or true is the 
information my physician gives 
about prohormones 
  
Very accurate 4 6.56% 
Somewhat accurate 9 14.75% 
Gives false information 4 6.56% 
Gives no information 42 68.85% 
I do not have a physician 2 3.28% 
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Table 13: Chi-square comparing prohormone to combination AAS users 
 Prohormone only Prohormone plus AAS P-value 
Age   0.53 
18-19 1 0  
20-24 9 8  
25-29 10 11  
30-39 12 5  
40-49 3 1  
50+ 1 0  
Physician use   0.36 
More than once per year 12 14  
Once a year 10 4  
Every other year or less 4 2  
Only when I am sick 10 5  
Comfortable speaking to a 
physician about prohormone use 
  0.37 
Yes 14 8  
Somewhat 6 8  
No 16 9  
My physician:    
Knowledgeable about prohormones   0.73 
A little or more 7 7  
Knows nothing 8 5  
I do not know 21 13  
Accuracy of information given   0.20 
Somewhat or more 5 8  
False information 2 2  
No information 29 15  
Physician in general:    
Knowledgeable about prohormones   0.43 
A little or more 12 9  
Knows nothing 10 10  
I don’t know 14 6  
Accuracy of information given:   0.05 
Very 0 0  
Somewhat 6 8  
False information 7 9  
No information 23 8  
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Table 14: Odds based on being a prohormone only user  
 OR  P-value CI 
Going to the physician 
yearly or more 
0.44 0.18 0.13-1.46 
My physician:    
At least somewhat 
accurate information 
0.44 0.24 0.11-1.75 
 Doctor knows at least a 
little about prohormones 
0.32 0.11 0.07-1.30 
Physicians in general:    
At least somewhat 
comfortable speaking to a 
physician about PH 
0.52 0.25 0.17-1.60 
Give no information 2.93 0.06 0.96-9.07 
 Doctors know at least a 
little about prohormones 
0.84 0.77 0.26-2.63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: FUTURE RESEARCH 
 
 
General Remarks 
 This study has been an exploration into an area of nutritional supplements that has 
hitherto gone largely unnoticed.  It is clear from this research that we have captured a 
group of prohormone users that are diverse in several ways.  Age ranges from twenties to 
more than fifty and use characteristics change with that age.  What we do not know is if 
the older individuals who use because they want to look better would have had other 
reasons if we asked them earlier in life.  The individuals seen here are experiencing a 
number of side effects.  Most of those seen to be relatively mild but some, such as 
gynecomastia, are permanent.  Also seen was a positive side effect of an increase in well-
being and this may have potential for helping explain why individuals take prohormones.  
Finally, we have seen a group that interacts with the health care system often.  They see 
physicians regularly, but are limited in how much they believe a physician’s information 
regarding the substances that they take.  This fact has implications for how a physician 
would treat a set of symptoms that seemingly have no explanation leading to unnecessary 
and potentially costly waste.  As a pilot study there are several ways in which this study 
could be improved upon which leads to the discussion of the future direction of this 
research. 
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Direction 
 After completion of this dissertation several points have come to light that impact 
my future research.  First is the refocusing and expanding of the study seen here.  The 
survey conducted gave insight into several factors that may improve the repeat survey 
including questions into perceived weight gain, perceived increases in strength, the 
impact of these substances on health, and a situational question asking into whether an 
individual would still use these substances if it was known that a severely negative side 
effect existed such as diabetes.  To achieve better results from the survey the research 
team will be pursuing grant opportunities to enable us to pay the research subjects and 
increase the number of participants.  Second is another area of similar research into 
prescription anabolic steroids.  Prescription testosterone use is also controversial and I 
will look into the outcomes of this use to see if there are negative outcomes associated 
with the substances and also if there are negative outcomes experienced by those who are 
testosterone deficient whom do not take prescription testosterone.   
Power 
 Much has been said in this dissertation about the lack of power due to sample 
size.  To help instruct the future implementation of this research I have done a sample 
size analysis.  To detect a 10 percent difference between two groups, given a two tail test, 
the survey needs at least 134 respondents in each group or 268 total.  To be safe the 
future study will aim to recruit approximately 300 respondents. 
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